<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467945</url>
  </required_header>
  <id_info>
    <org_study_id>EMR200763_003</org_study_id>
    <nct_id>NCT03467945</nct_id>
  </id_info>
  <brief_title>Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants</brief_title>
  <official_title>Randomized, Open Label, Single Dose, 4 Treatment, 4 Period, Crossover Design (4 x 4) Trial to Evaluate the Bioequivalence and Secondarily Drug - Drug Interaction of Fixed Combination of Metformin Tablets 1000 mg/Gliclazide 30 mg MR, Compared With the Co-administration of Individual Tablets and Individual Administration of Each Single Tablet (Metformin 1000 mg XR and Gliclazide 30 mg MR) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the bioequivalence and drug-drug interaction of
      Metformin/Gliclazide fixed combination tablet compared to co-administration of individual
      tablets of Metformin and Gliclazide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2018</start_date>
  <completion_date type="Actual">April 29, 2018</completion_date>
  <primary_completion_date type="Actual">April 29, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin and Gliclazide</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Metformin and Gliclazide</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Metformin and Gliclazide</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Ke) for Metformin and Gliclazide</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life of Metformin and Gliclazide</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/f) for Metformin and Gliclazide</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Residence Time for Metformin and Gliclazide</measure>
    <time_frame>Pre-dose up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Day 71</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin and Gliclazide fixed combination tablet in treatment period 1 followed by individual tablets of Metformin and Gliclazide in treatment period 2 followed by Metformin tablet in treatment period 3 and then Gliclazide tablet in treatment period 4. Each treatment period will be separated by a 14 day wash-out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individual tablets of Metformin and Gliclazide in treatment period 1 followed by Gliclazide tablet in treatment period 2 followed by Metformin and Gliclazide fixed combination tablet in treatment period 3 and then Metformin tablet in treatment period 4. Each treatment period will be separated by a 14 day wash-out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin tablet in treatment period 1 followed by Metformin and Gliclazide fixed combination tablet in treatment period 2 followed by Gliclazide tablet in treatment period 3 and then individual tablets of Metformin and Gliclazide in treatment period 4. Each treatment period will be separated by a 14 day wash-out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gliclazide tablet in treatment period 1 followed by Metformin tablet in treatment period 2 followed by individual tablets of Metformin and Gliclazide in treatment period 3 and then Metformin and Gliclazide fixed combination tablet in treatment period 4. Each treatment period will be separated by a 14 day wash-out period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin/Gliclazide Fixed Combination</intervention_name>
    <description>Participants will receive single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Participants will receive single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide</intervention_name>
    <description>Participants will receive single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants has given written informed consent before any study-related activities
             are carried out

          -  Ethnic origin: Mexicans

          -  Weight between 55 and 95 kilogram (kg)

          -  Body mass index between 18.5 and 27 kilogram per meter square (kg/m^2)

          -  Not smoking more than 5 cigarettes or 1 cigar or 1 pipe per day (or non smokers)

          -  Good physical and mental health status

          -  Vital signs (blood pressure and pulse) in supine position within the normal range or
             showing no clinically relevant deviation as judged by the Investigator

          -  Electrocardiogram recording (12-lead) without signs of clinically relevant pathology
             in particular QTc (Bazett) &lt;450 milliseconds (ms)

          -  All values for biochemistry and hematology tests of blood and urine within the normal
             range or showing no clinically relevant deviation as judged by the Investigator

          -  All women of childbearing potential (WOCBP) are not nursing, are not pregnant, and are
             using highly effective methods of birth control for a period of at least one month
             before and after dosing

          -  All women of childbearing potential must have negative tests for pregnancy at
             screening, and at day -1 for each treatment period and at end of trial (EOT)

          -  Negative screen for alcohol and drugs of abuse at Screening and on each admission

          -  Negative screen for Hepatitis B surface (HBs) antigens, Hepatitis C Virus (HCV)
             antibodies, Hepatitis A Virus (HAV) antibodies and Human Immunodeficiency Virus (HIV)
             1 and 2 antibodies

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participation in a clinical trial within 90 days prior to first drug administration

          -  Participants who have donated more than 500 milliliter (mL) of blood or who have lost
             significantly (more than 450 mL) blood within 90 days prior to first drug of
             administration

          -  Any surgical or medical condition, constitutes a risk or a contraindication for the
             participation of the participant in the study or that could interfere with the study
             objectives, conduct or evaluation

          -  History of surgery of the gastrointestinal tract

          -  Allergy

          -  Receipt of any prescription or non-prescription medication within 2 weeks before the
             first study drug administration

          -  Renal failure or renal dysfunction (creatinine clearance less than [&lt;] 80 mL/minute)
             as assessed by using the estimated measure with the Cockcroft-Gault formula

          -  Known lack of participant compliance or inability to communicate or cooperate with the
             Investigator

          -  Considerable diet deviations from normal nutritional patterns

          -  Consumption of large quantities of methylxanthine-containing beverages (more than 600
             milligram [mg] caffeine / day: one cup [240 mL] of coffee contains approx. 100 mg of
             caffeine, one cup of tea approximately 30 mg and one glass of cola approximately 20 mg
             caffeine)

          -  Consumption of grapefruit, orange, cranberry or juices of these fruits, 14 days prior
             to drug administration and during the study

          -  Legal incapacity or limited legal capacity

          -  Participants kept in detention

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Please Contact the Merck KGaA Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <zip>64293</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Gliclazide</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Drug-drug Interaction</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

